Pitfalls in antiprotease therapy of emphysema - PubMed (original) (raw)
Review
Pitfalls in antiprotease therapy of emphysema
G L Snider et al. Am J Respir Crit Care Med. 1994 Dec.
Abstract
Many individuals with emphysema are unable to stop smoking despite the best efforts of specialists in smoking cessation. Because emphysema is a slowly progressive disease, it is rational to attempt to develop drugs for it. The hope is that drug therapy will slow the rate of decline of lung function, thereby delaying the onset of disability and prolonging life. The major emphasis in drug development has been on antiproteases having the ability to inhibit neutrophil elastase. There are a number of potential pitfalls in the development of such drugs. Although there is gathering evidence that elastin degradation is a part of the development of human emphysema, it is evident from studies in experimental emphysema that protease-antiprotease imbalance is not the only pathogenetic mechanism that gives rise to emphysema. There is strong evidence that human centrilobular and panacinar emphysema are different in pathogenesis. Indeed, airspace enlargement may be considered one of the stereotyped ways that the lung heals after a variety of injuries. There is accumulating evidence that macrophages as well as neutrophils may participate in elastolysis; antiproteases designed to inhibit neutrophil elastase may not inhibit the metalloproteases produced by macrophages. Some antiproteases may serve to transport elastase into the interstitium of the lung and actually increase the risk of emphysema. A process study of antiprotease therapy, using a measure of alteration of elastase burden of the lungs and urinary elastin peptides and desmosine measurements as markers of elastin degradation is now feasible. An outcome study of antiprotease therapy of emphysema should not be undertaken unless there is evidence from a process study that an antiprotease has biochemical efficacy and no unacceptable side effects.
Similar articles
- The specific treatment of emphysema.
Snider GL, Stone PJ, Lucey EC. Snider GL, et al. Eur Respir J Suppl. 1990 Mar;9:23s-28s. Eur Respir J Suppl. 1990. PMID: 2187448 Clinical Trial. - Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema.
Abboud RT, Vimalanathan S. Abboud RT, et al. Int J Tuberc Lung Dis. 2008 Apr;12(4):361-7. Int J Tuberc Lung Dis. 2008. PMID: 18371259 Review. - Two decades of research in the pathogenesis of emphysema.
Snider GL. Snider GL. Schweiz Med Wochenschr. 1984 Jun 23;114(25):898-906. Schweiz Med Wochenschr. 1984. PMID: 6379868 Review. - Possible mechanisms of emphysema in smokers: cigarette smoke condensate suppresses protease inhibition in vitro.
Janoff A, Carp H. Janoff A, et al. Am Rev Respir Dis. 1977 Jul;116(1):65-72. doi: 10.1164/arrd.1977.116.1.65. Am Rev Respir Dis. 1977. PMID: 301725
Cited by
- Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease.
Alam S, Li Z, Atkinson C, Jonigk D, Janciauskiene S, Mahadeva R. Alam S, et al. Am J Respir Crit Care Med. 2014 Apr 15;189(8):909-31. doi: 10.1164/rccm.201308-1458OC. Am J Respir Crit Care Med. 2014. PMID: 24592811 Free PMC article. - IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13.
Kang MJ, Choi JM, Kim BH, Lee CM, Cho WK, Choe G, Kim DH, Lee CG, Elias JA. Kang MJ, et al. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1205-17. doi: 10.1164/rccm.201108-1545OC. Epub 2012 Mar 1. Am J Respir Crit Care Med. 2012. PMID: 22383501 Free PMC article. - Interferon gamma induction of pulmonary emphysema in the adult murine lung.
Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA. Wang Z, et al. J Exp Med. 2000 Dec 4;192(11):1587-600. doi: 10.1084/jem.192.11.1587. J Exp Med. 2000. PMID: 11104801 Free PMC article. - Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema.
Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, Chapman HA Jr, Shapiro SD, Elias JA. Zheng T, et al. J Clin Invest. 2000 Nov;106(9):1081-93. doi: 10.1172/JCI10458. J Clin Invest. 2000. PMID: 11067861 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources